From PsychonautWiki
(Redirected from Acacia confusa rootbark)
Jump to navigation Jump to search
Summary sheet: DMT
Chemical Nomenclature
Common names DMT, N,N-DMT, "Dmitry", "The Glory", "The Spirit Molecule"
Substitutive name N,N-Dimethyltryptamine
Systematic name 2-(1H-Indol-3-yl)-N,N-dimethylethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 2 - 10 mg
Light 10 - 20 mg
Common 20 - 40 mg
Strong 40 - 60 mg
Heavy 60+ mg
Total 5 - 20 minutes
Onset 20 - 40 seconds
Come up 1 - 3 minutes
Peak 2 - 8 minutes
Offset 1 - 6 minutes
After effects 10 - 60 minutes

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


N,N-Dimethyltryptamine (also known as DMT, N,N-DMT and "The Spirit Molecule") is a naturally-occurring psychedelic substance of the tryptamine class that produces uniquely powerful and short-lived psychedelic effects when administered.[1]

Depending on the dosage and method of administration, the effects of DMT can range from mild psychedelic states to powerfully immersive life-altering experiences which are often described as the ultimate displacement from ordinary consciousness in which users are placed in a subjective state where they can experience exploring ineffable spiritual realms or alternate dimensions.[2]

DMT is present in over 65 species of plants and has been identified as being a normal constituent of human metabolism and an endogenous neurotransmitter in certain rodents. Its presence is also known to be widespread throughout the plant kingdom.[3][4] Although various theories have been postulated, its neurobiological function has yet to be determined.[citation needed]

In modern times, DMT is known as an extremely powerful visionary psychedelic entheogen that, when vaporized or smoked, produces short-lived effects with a very rapid onset that is sometimes described as an "impossibly high-speed rollercoaster ride." When ingested in combination with a MAOI or RIMA agent, it becomes active orally and significantly longer lasting, immersive, and interactive in nature: this combination is known as ayahuasca.[5] Ayahuasca brews have been used traditionally in South America since at least around the year 1500.[6]

Unlike most highly prohibited substances, DMT is not considered to be addictive or toxic by the scientific community.[7][8] Nevertheless, unpredictable adverse reactions such as uncontrollable anxiety, delusions and psychosis can always occur, particularly among those predisposed to mental disorders.[9] While these negative reactions or "bad trips" can often be attributed to user inexperience or improper preparation of set and setting, they have been known to happen spontaneously among even highly experienced users as well. It is therefore highly advised to use harm reduction practices if using this substance.

DMT Crystals[10]

History and culture

DMT was first synthesized in 1931 by the German chemist Richard Helmuth Fredrick Manske.[11][12] Its discovery as a natural product is generally credited to Brazilian chemist and microbiologist Oswaldo Gonçalves de Lima who, in 1946, isolated an alkaloid he named nigerina (nigerine) from the root bark of jurema preta (Mimosa tenuiflora).[12][13][14] DMT was unequivocally identified in 1959, when American chemists were provided a sample of Mimosa tenuiflora.[15][16] DMT was also isolated and formally identified in the seeds and pods of Anadenanthera peregrina by a team of American chemists led by Evan Horning in 1955.[15][17]

Since 1955, DMT has been found in a host of organisms: in at least fifty plant species belonging to ten families,[18] and in at least four animal species, including one gorgonian[19] and three mammalian species.


Substitutive structure of a tryptamine molecule

DMT, or N,N-dimethyltryptamine, is a naturally-occurring indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. DMT contains two methyl groups (CH3-) bound to the terminal amine RN at the end of this chain. DMT has many homologs and analogs from base tryptamines like MET and DPT, to four and five position substituted variants such as 4-PO-DMT (Psilocybin), 4-AcO-DMT (Psilacetin), and 5-MeO-DMT.


Further information: Serotonergic psychedelic

DMT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

In addition to this, N,N-dimethyltryptamine is believed to be an endogenous ligand for the sigma receptor. However, the significance of the sigma-1 receptor remains the subject of ongoing scientific research.[20]

Subjective effects

DMT in its smokeable form is reported to be the least mentally inebriating psychedelic. It is due to a lack of perceived intoxication that many people describe DMT as a genuine experience that is actually happening to them. It is worth noting that many people report that smoked DMT is extremely clear-headed in its style and tends to produce less personal insight in comparison to orally active psychedelics such as ayahuasca, LSD and psilocybin due to its short-acting nature.

Disclaimer: The effects listed below are cited from the subjective effect index, which is based on anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be treated with a healthy degree of skepticism. It is worth noting that these effects will rarely (if ever) occur all at once, although higher doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects

Visual effects

Cognitive effects

Auditory effects

Multi-sensory effects

Transpersonal effects

Progressive stages

When smoked or vaporized at moderate to heavy dosages, the DMT experience consistently manifests itself in a progressive sequence which can be described as follows:

1. "Breaking Through"

The first step of a DMT trip is the come up that leads onto an experience commonly referred to as "breaking through."[22] This seems to have at least a few different ways of presenting itself to the user.

The first thing that a person notices is an extremely distinct set of visual enhancements such an increase in visual acuity and colour intensity. This is followed by a sudden onset of high level 3 geometry which increases in its intensity until it envelopes and covers the external environment. These effects are often accompanied by auditory hallucinations such as soft crackling sounds or high pitched extended tones. There is also the possibility of accompanying physical sensations as one "breaks through." These can include feelings of suddenly being pushed through and onto the other side of a membrane or feelings of shooting through space at high speeds.

2. "The Waiting Room"

Almost immediately after a person has inhaled enough DMT to have "broken through", they often find themselves spending a brief amount of time in what is sometimes described as a psychedelic "waiting room" or "loading screen." The appearance of this space can assume a seemingly infinite variety of forms but generally appears in the shape of an enveloping tunnel comprised of rapidly shifting, interlocking geometry. This lasts approximately 10 – 20 seconds and feels qualitatively different from other stages of the experience.

3. "The Other Side"

Once the waiting period is over, the user will feel that they have "broken through" onto the other side. It is here where users experience intense level 7 geometry and level 3 - 4 internal hallucinations. It is worth noting that although experiences vary between individuals, DMT trips often follow common archetypes, scenarios, content, and plots. These scenarios generally consist of visiting what appears to be an alternate reality that is often described to contain autonomous entities, settings, sceneries, and landscapes as well as themes of a cosmic, transcendental, or transpersonal nature.

4. "Drifting Down"

The final stage is experienced as the sensation of being pulled further and further away from the scenario until it is no longer visible and one finds themselves back in reality. This is typically accompanied by level 3 - 4 geometry as well as a sense of general exhilaration and awe. The moderate to mild geometry stays for a further 10 – 15 minutes before disappearing completely, sometimes leaving a noticeable "body high" that lingers for up to an hour.

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Natural plant sources

Main article: DMT-containing plants

Mimosa hostilis root bark

Further information: Mimosa tenuiflora (botany)
Mimosa hostilis root bark.

Mimosa hostilis (also known as Mimosa tenuiflora, Jurema and Tepezcohuite) is a perennial tree or shrub native to the northeastern region of Brazil and is found as far north as southern Mexico. Around 1% of the dried weight is DMT. It is legal to purchase online in many parts of the world and a commonly used source for performing DMT extractions or brewing into ayahuasca.

Acacia confusa root bark.

Acacia confusa root bark

Further information: Psychoactive acacias

Acacia confusa (also known as Acacia Petit Feuille, Small Philippine Acacia, Formosa Acacia (Taiwan Acacia) and Formosan Koa) is a perennial tree native to South-East Asia. It is legal to purchase online and easily accessible in many parts of the world. The plant matter itself contains the following chemicals:[23]

  • N-Methyltryptamine: 1.43% (not psychoactive without MAOI)
  • DMT: 1.15%

Preparation methods

Preparation methods for this substance found within our tutorial index include:


Dr. Rick Strassman has hypothesized that the pineal gland is responsible for the production and release of DMT which he believes possibly could be excreted in large quantities at the moments of birth and death.[13] However, this view was contested by David E. Nichols in 2018, who argued that the pineal gland secretes insufficient amounts of DMT to produce psychoactive effects.[24] In 2019, a study by Jimo Borjigin demonstrated in rat brains that brain neurons with the two enzymes required to make DMT were not just in the pineal gland but also in the neocortex and hippocampus.[25]


In 2018, a study demonstrated neuroplasticity induced by DMT and other psychedelics through TrkB, mTOR, and 5-HT2A signaling.[26]

Toxicity and harm potential

DMT is considered to be non-addictive, is not associated with any form of neurotoxicity, and has an extremely low toxicity relative to dose. As with other psychedelic substances, there are relatively few physical side effects associated with acute DMT exposure. Various studies have shown that in reasonable doses in a careful context, it has little to no negative cognitive, psychiatric or physical consequences.[13]

However, as with psychedelics generally, DMT is thought to be able to act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are advised not to use this substance unless under medical supervision.

Despite the lack of physical risks, it is highly advised to approach this substance with extreme caution and harm reduction practices.

Lethal dosage

The median lethal dose (LD50) of DMT in humans has never been reached in any setting, nor is this expected to change due to its pharmacological properties.

Dependence and abuse potential

Like other serotonergic psychedelics, DMT is considered to be non-addictive with a low abuse potential.[13] There are no literature reports of successful attempts to train animals to self-administer DMT — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence.[27] Likewise, there is virtually no withdrawal syndrome when chronic use of DMT is stopped.[citation needed]

Notably, tolerance to the effects of DMT does not appear to occur. The reason for this is unknown. Likewise, DMT does not produce cross-tolerance with other psychedelics, meaning that after the consumption of DMT psychedelics will not have a reduced effect.

Dangerous interactions

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when taken with other substances. The following lists some known dangerous combinations, but cannot be guaranteed to include all of them. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.

  • Cannabis - Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics. It strongly intensifies the sensory and cognitive effects of DMT. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like anxiety, confusion and psychosis. Users are advised to start off with only a fraction of their usual cannabis dose and take long breaks between hits to avoid over intake.
  • Amphetamines & Cocaine - Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences.
  • Tramadol - Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.

Legal status

Internationally, DMT is classified as a Schedule I drug under the United Nations 1971 Convention on Psychotropic Substances, meaning that international trade in DMT is supposed to be closely monitored and its use is supposed to be restricted to scientific research and medical use. Natural materials containing DMT, including ayahuasca, are not regulated under the 1971 Psychotropic Convention.[28][29]

  • Australia: Between 2011 and 2012, the Australian government was considering changes to the Australian Criminal Code that would classify any plants containing any amount of DMT as "controlled plants".[30]
  • Austria: DMT is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).[citation needed]
  • Brazil: DMT is illegal to possess, produce and sell under Portaria SVS/MS nº 344.[31] Rules are relaxed regarding religious use.[citation needed]
  • Canada: DMT is a Schedule III drug.[32]
  • Denmark: DMT is a Category B drug.[33]
  • Estonia: DMT is a Schedule I drug.[citation needed]
  • Germany: DMT is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of January 24, 1974.[34][35] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[36]
  • Hungary: DMT is illegal to possess, produce and sell.[37]
  • Latvia: DMT is a Schedule I drug.[38]
  • New Zealand: DMT is classified in New Zealand as a Class A drug under the Misuse of Drugs Act 1975.[39]
  • Norway: DMT is a Schedule I drug.[citation needed]
  • Russia: DMT is illegal to possess, produce and sell.[citation needed]
  • United Kingdom: DMT is a Class A drug.[40]
  • United States: DMT is a Schedule I drug.[citation needed] Rules are relaxed regarding religious use, however. In the US, dried root bark of Mimosa hostilis had been considered a "grey area" item for a long time. However, recent efforts by the DEA appear to be focusing on eliminating internet sales of the bark, citing 21 USC § 841, which states that "(IV) any compound, mixture, or preparation which contains any quantity of any of the substances referred to in subclauses (I) through (III)" is also considered an illegal substance. Many USA based vendors have since been stocking Acacia confusa bark as a result due to its very similar alkaloid content.[citation needed]

See also

External links




  1. Nichols, D. E. (2016). Psychedelics, (April), 264–355.
  2. Gallimore AR, Strassman RJ. A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience. Frontiers in Pharmacology. 2016;7:211.
  3. Ott, Jonathan (1994). Ayahuasca Analogues: Pangæan Entheogens (1st ed.). Kennewick, WA, USA: Natural Products. pp. 81–3.
  4. Shulgin, Alexander; Shulgin, Ann (1997). "DMT is Everywhere". (page 277) TiHKAL: The Continuation (1st ed.).
  5. Strassman, R. J. (1995). Human psychopharmacology of N, N-dimethyltryptamine. Behavioural Brain Research, 73(1), 121-124.
  6. Erowid - DMT Basics |
  7. Lüscher, C., & Ungless, M. A. (2006). The Mechanistic Classification of Addictive Drugs, 3(11).
  8. Nichols, D. E. (2016). Psychedelics, (April), 264–355.
  9. Strassman, R. J. (1984). Adverse reactions to psychedelic drugs. A review of the literature. The Journal of Nervous and Mental Disease, 172(10), 577-595. PMID: 6384428
  10. Q21Q21. (2014, September). Q21Q21 DMT Crystal Extraction Results. Retrieved from
  11. Manske R.H.F. (1931). "A synthesis of the methyltryptamines and some derivatives". Canadian Journal of Research. 5 (5): 592–600. doi:10.1139/cjr31-097. 
  12. 12.0 12.1 Bigwood J.; Ott J. (November 1977). "DMT: the fifteen minute trip". Head. 2 (4): 56–61. Archived from the original on 2006-01-27. Retrieved 2010-11-28. 
  13. 13.00 13.01 13.02 13.03 13.04 13.05 13.06 13.07 13.08 13.09 13.10 13.11 Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Kellner, R. (1994). Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. Subjective Effects and Preliminary Results of a New Rating Scale. Archives of General Psychiatry, 51(2), 98-108. PMID: 8297217. Cite error: Invalid <ref> tag; name "strassman" defined multiple times with different content
  14. Ott, Jonathan (1996). Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History (2nd, densified ed.). Kennewick, WA: Natural Products. ISBN 978-0-9614234-9-0. 
  15. 15.0 15.1 Cite error: Invalid <ref> tag; no text was provided for refs named ott1998
  16. Pachter I.J.; Zacharias D.E.; Ribeiro O. (September 1959). "Indole alkaloids of Acer saccharinum (the silver maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis". Journal of Organic Chemistry. 24 (9): 1285–87. doi:10.1021/jo01091a032. 
  17. Fish M.S.; Johnson N.M.; Horning E.C. (November 1955). "Piptadenia alkaloids. Indole bases of P. peregrina (L.) Benth. and related species". Journal of the American Chemical Society. 72 (22): 5892–95. doi:10.1021/ja01627a034. 
  18. Ott, Jonathan (1994). Ayahuasca Analogues: Pangæan Entheogens (1st ed.). Kennewick, WA, USA: Natural Products. pp. 81–3. ISBN 978-0-9614234-5-2. OCLC 32895480. 
  19. Cimino G.; De Stefano S. (1978). "Chemistry of Mediterranean gorgonians: simple indole derivatives from Paramuricea chamaeleon". Comparative Biochemistry and Physiology C. 61 (2): 361–2. doi:10.1016/0306-4492(78)90070-9. 
  20. Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009). The Hallucinogen N, N-dimethyltryptamine (DMT) Is An Endogenous Sigma-1 Receptor Regulator. Science, 323(5916), 934-937.
  21. Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Kellner, R. (1994). Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. Subjective Effects and Preliminary Results of a New Rating Scale. Archives of General Psychiatry, 51(2), 98-108. PMID: 8297217.
  22. "DMT breaking through" Google search |,ssl&ei=VuafVquUB8H_UOi9v_AJ
  23. Acacia Confusa | Root Bark – Alkaloids – Distribution – Growing ( |
  26. Ly, Calvin; Greb, Alexandra C.; Cameron, Lindsay P.; Wong, Jonathan M.; Barragan, Eden V.; Wilson, Paige C.; Burbach, Kyle F.; Soltanzadeh Zarandi, Sina; Sood, Alexander; Paddy, Michael R.; Duim, Whitney C.; Dennis, Megan Y.; McAllister, A. Kimberley; Ori-McKenney, Kassandra M.; Gray, John A.; Olson, David E. (2018). "Psychedelics Promote Structural and Functional Neural Plasticity". Cell Reports. 23 (11): 3170–3182. doi:10.1016/j.celrep.2018.05.022. ISSN 2211-1247. 
  27. Cite error: Invalid <ref> tag; no text was provided for refs named hallucinogens
  28. UN General Assembly, 1971 Convention on Psychotropic Substances, 9 December 1975, A/RES/3443.
  29. Schaepe, Herbert (2001). "International control of the preparation "ayahuasca"" (JPG). Erowid. Retrieved November 29, 2010. | [1]
  30. Consultation on implementation of model drug schedules for Commonwealth serious drug offenses". Australian Government, Attorney-General’s Department. 24 June 2010. |
  32. Controlled Drugs and Substances Act of Canada
  34. "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019. 
  35. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019. 
  36. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019. 
  37. DMT-N,N dimetil-triptamin -
  38. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) |
  39. Misuse of Drugs Act 1975 |
  40. Misuse of Drugs Act 1971 ( |